Recent Price Movement and Market Performance
Evexia Lifecare’s stock has been on a downward trajectory over multiple time horizons. In the past week, the share price fell by 6.71%, underperforming the Sensex’s 5.52% decline. The trend extends over longer periods, with the stock losing 12.03% in the last month and 15.24% year-to-date, both figures exceeding the respective Sensex declines of 9.76% and 12.50%. Most strikingly, the stock has plummeted 45.70% over the last year, while the Sensex posted a modest gain of 1.00% during the same period. This stark contrast highlights the company’s struggles amid a generally resilient market environment.
Today, the stock hit a new 52-week low of ₹1.37, signalling sustained selling pressure. It also underperformed its sector by 3.29%, reinforcing the notion that investors are favouring other stocks within the same industry. Technical indicators further compound the bearish outlook, with the share price trading below all key moving averages—5-day, 20-day, 50-day, 100-day, and 200-day—suggesting a lack of short- and long-term momentum.
Investor participation has also waned considerably. Delivery volume on 12 Mar was 25.75 lakh shares, representing a sharp 69.77% decline compared to the five-day average delivery volume. This drop in trading activity may indicate reduced investor interest or confidence, which often exacerbates price declines.
This week's revealed pick, a Large Cap from Public Banks with TARGET PRICE, is already showing movement! Get the complete analysis before it's too late.
- - Target price included
- - Early movement detected
- - Complete analysis ready
Fundamental Challenges Weighing on the Stock
Evexia Lifecare’s financial health and operational performance have been underwhelming, contributing to the stock’s persistent decline. The company’s return on capital employed (ROCE) stands at a mere 0.1%, indicating minimal efficiency in generating profits from its capital base. Although the stock trades at a discount relative to its peers’ historical valuations, this valuation gap appears justified given the company’s deteriorating profit metrics.
Over the past year, profits have contracted sharply by 60.3%, a significant erosion that has not gone unnoticed by investors. This decline in profitability is mirrored in the company’s weak return on equity (ROE), averaging just 0.88%, which signals poor returns generated on shareholders’ funds. Furthermore, the company’s ability to service debt is limited, with a high Debt to EBITDA ratio of -1.00 times, underscoring financial strain and elevated leverage risks.
Long-term growth prospects also appear bleak. Operating profits have shrunk at a compounded annual growth rate (CAGR) of -23.63% over the last five years, reflecting sustained operational challenges. This weak fundamental strength has led to the stock underperforming not only the Sensex but also the broader BSE500 index across multiple periods, including the last three years and one year.
Recent quarterly results have been flat, with no significant improvement in December 2025, further dampening investor sentiment. The majority of shareholders are non-institutional, which may limit the stock’s liquidity and institutional support during turbulent periods.
Holding Evexia Lifecare from Edible Oil? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Conclusion: Why the Stock Is Falling
The decline in Evexia Lifecare’s share price on 13-Mar is a reflection of deep-rooted fundamental weaknesses and disappointing financial performance. The company’s inability to generate consistent profits, coupled with poor returns on equity and capital employed, has eroded investor confidence. Its underperformance relative to market benchmarks and sector peers, alongside technical indicators signalling bearish momentum, has further pressured the stock.
Falling investor participation and a new 52-week low reinforce the negative sentiment surrounding the stock. While the valuation discount might attract some value investors, the persistent decline in profits and weak long-term growth prospects suggest caution. Without a clear turnaround in operational and financial metrics, the stock is likely to remain under pressure in the near term.
Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →
